Nifuroxazide exerts potent anti-tumor and anti-metastasis activity in melanoma

• Published in: Scientific reports Vol. 6; no. 1; p. 20253
• Main Authors: Zhu, Yongxia, Ye, Tinghong, Yu, Xi, Lei, Qian, Yang, Fangfang, Xia, Yong, Song, Xuejiao, Liu, Li, Deng, Hongxia, Gao, Tiantao, Peng, Cuiting, Zuo, Weiqiong, Xiong, Ying, Zhang, Lidan, Wang, Ningyu, Zhao, Lifeng, Xie, Yongmei, Yu, Luoting, Wei, Yuquan
• Format: Journal Article
• Language: English
• Published: London Nature Publishing Group UK 02.02.2016; Nature Publishing Group
• Subjects: 13/2; 13/31; 13/51; 14/34; 631/67/1059; 631/80/84; 64/60; Animals; Antineoplastic Agents - pharmacology; Apoptosis; Apoptosis - drug effects; Cell adhesion & migration; Cell Line, Tumor; Cell migration; Cell Movement - drug effects; Cell Proliferation; Cell Survival - drug effects; Disease Models, Animal; Drug resistance; G2 Phase Cell Cycle Checkpoints - drug effects; Gelatinase B; Humanities and Social Sciences; Humans; Hydroxybenzoates - pharmacology; Matrix metalloproteinase; Melanocytes; Melanoma; Melanoma - drug therapy; Melanoma - metabolism; Melanoma - pathology; Melanoma, Experimental; Metalloproteinase; Metastases; Metastasis; Mitochondria - drug effects; Mitochondria - metabolism; multidisciplinary; Neoplasia; Neoplasm Metastasis; Nitrofurans - pharmacology; Science; Side effects; Signal transduction; Src protein; Stat3 protein; Suppressor cells; Transcription; Tumors; Vimentin; Xenograft Model Antitumor Assays

Melanoma is a highly malignant neoplasm of melanocytes with considerable metastatic potential and drug resistance, explaining the need for new candidates that inhibit tumor growth and metastasis. The signal transducer and activator of the transcription 3 (Stat3) signaling pathway plays an important...